Log In
Print
BCIQ
Print
Print this Print this
 

UCART19

  Manage Alerts
Collapse Summary General Information
Company Cellectis S.A.
DescriptionChimeric antigen receptor (CAR)-modified CD19-targeted allogeneic T cells
Molecular Target CD19
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Non-stem cell
Latest Stage of DevelopmentPreclinical
Standard IndicationChronic lymphocytic leukemia (CLL)
Indication DetailsTreat chronic lymphocytic leukemia (CLL)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today